Loading stock data…
PTN
$13.50-0.70 (-4.93%)
Market OpenUpdated 12:50 PM EDT
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Palatin Technologies, Inc. in the Healthcare sector is trading at $13.50. Wall Street consensus targets $53.50 (3 analysts), implying a +296.3% move over the next 12 months. The stock is currently 56% below its 52-week high of $31.00, remaining 13.1% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +296.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.92M↑ | $116,036↓ | $8.85M | $0 | $0 |
| Gross Profit | — | — | — | $0 | $0 |
| Operating Income | -$1.58M↑ | -$7.33M↓ | $4.66M↑ | -$4.60M↑ | -$5.23M |
| Net Income | -$1.43M↑ | -$7.26M↓ | $4.68M↑ | -$2.23M↑ | -$4.81M |
Peer Comparison
JNJUNHPFE
Fundamentals
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonis...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-59.00%
Volume
Today's trading volume
5,299
Recent News
Palatin Technologies Inc (PTN) Q3 2026 Earnings Call Highlights: Strategic Advances Amidst ...
Palatin Technologies Inc (PTN) reports significant revenue growth and strategic partnerships, while navigating increased expenses and development delays.
Transcript: Palatin Techs Q3 2026 Earnings Conference Call
Palatin Techs (AMEX:PTN) held its third-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit https://www.benzinga.com/apis/ to learn more. Access the full call at https://www.webcaster5.com/Webcast/Page/2953/54002 Summary Palatin Techs reported $3.9 million in collaboration and license revenue for Q3 2026, marking an increase from no revenue in the prior year, p
Palatin Technologies, Inc. Q2 2026 Earnings Call Summary
Moby summary of Palatin Technologies, Inc.'s Q2 2026 earnings call
Palatin Technologies Inc (PTN) Q2 2026 Earnings Call Highlights: Strategic Advances Amid Rising ...
Despite a significant net loss, Palatin Technologies Inc (PTN) strengthens its financial position with a successful public offering and advances in its obesity treatment pipeline.